91.9%
ICBMelanomanon-small-cell lung cancerStanford University
…7 and 38, which is reflective of this patient‘s non-response to ICB therapyAbstract 103 Figure 2Mapping of PD1/PD-L1 interactions T…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 841–900 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
HFNO4Impella4MRTX11334Metoclopramide4Midodrine4NA4Pravastatin4Risperidone4Surfactant4chlorhexidine4intravenous morphine4ENDS4Epcoritamab4FLT3L4Febuxostat4Pertuzumab4TIraGolumab4anti-PD-14topotecan4AED4Dapirolizumab pegol4Mesalamine4Peptides4S-Ketamine4Valsalva4cefazolin4fosfomycin4gabapentinoid4siltuximab4zimberelimab4AC4Budesonide orodispersible tablets4CAR-T4Chemsex4Enalapril4G-CSF4GHB/GBL4IFN-β4Isoprenaline4Methacholine4PD-14Talimogene laherparepvec4cholecalciferol4glucagon4nicotine pouches40.25% bupivacaine4ART4Anti-centromere4Comaneci4DMTs4GCs4ICG4IL-174IV methylprednisolone4Ivabradine4Loop diuretics4Natriuretic Peptide4Nitrofurantoin4PE4Ribavirin4
Articles mentioning drugs
10,506 articles · page 564 of 876corticosteroidscytokine inhibitorscanceradvanced malignanciestumor
…tments often consist of broad immunosuppressive agents, such as corticosteroids and cytokine inhibitors, which have been shown to potentially d…
82.0%
DMSOmonoclonal antibodiesMycoplasma contamination
…luding those with high cell density and cryoprotectants such as DMSO.…
ICIsImmune checkpoint inhibitorsstage III melanomaJAMA OncolJAMA Network Open
…Background Immune checkpoint inhibitors (ICIs) have transformed the management of stage III melanoma, offerin…
ipilimumabnivolumabmelanomamelanoma-specifictertiary care center
…, Wai ES, et al. Survival outcomes following discontinuation of ipilimumab and nivolumab for advanced melanoma in a population-based cohor…
immune checkpoint inhibitorsmelanomaHodgkin lymphomanon-small cell lung cancerhepatocellular carcinomahead and neck squamous cell carcinomarenal cell carcinomaRCC
… Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):…
infliximabrituximabmyasthenia gravismyocarditismyositisir-myocarditisir-myositis
…ICT clearance), rituximab (anti-CD20 for B-cell depletion), and infliximab (anti-TNF-a for T-cell and potential myeloid suppression). We h…
ICIimmune checkpoint inhibitorJohns Hopkins HospitalJHHOncology Evaluation and Treatment Center
… use was conducted, identifying 737 patients actively receiving ICI therapy and 67 active irAE encounters. Root cause analysis, inc…
pembrolizumabnivolumabNSCLCnon-small cell lung cancerCohort 1Cohort 2TriNetX Global Collaborative NetworkSLERApsoriasis+1 more
…cluded patients who received at least one ICI (e.g., nivolumab, pembrolizumab); Cohort 2 included those who did not. Propensity score matchin…
NACbreast cancerBCHER2-negative BCTNBC
…on from three cohorts of HER2-negative BC patients treated with NAC, validating model generalizability. We systematically assessed …
immune checkpoint inhibitorsICIsnon-small cell lung cancerneoadjuvant chemotherapyTianjin Medical University Cancer Institute and HospitalNSCLC
…SCLC) patients receiving neoadjuvant chemotherapy combined with immune checkpoint inhibitors (ICIs).Methods Cases meeting inclusion criteria were divided in…
PD-L1 ICIsimmune checkpoint inhibitors (ICIs)Providence Health SystemWest Cancer Centermetastatic melanomaaNSCLCES-SCLCEuropean Unionadvanced non-small cell lung cancerkidney cancer+3 more
…l CTRS to 243 patients with advanced-stage cancers treated with PD-L1 ICIs at Providence Health System and West Cancer Center, including 8…